Barclays PLC Werewolf Therapeutics, Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 13,236 shares of HOWL stock, worth $21,574. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,236
Previous 13,236
-0.0%
Holding current value
$21,574
Previous $14,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding HOWL
# of Institutions
65Shares Held
23.6MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA6.68MShares$10.9 Million0.16% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.31MShares$7.03 Million10.84% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.41MShares$3.93 Million0.51% of portfolio
-
Bank Of America Corp Charlotte, NC2.13MShares$3.47 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.59MShares$2.59 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $48.1M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...